Nociceptin receptor agonists - Pipeline Insight, 2024

Nociceptin receptor agonists - Pipeline Insight, 2024

DelveInsight’s, “Nociceptin receptor agonists - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Nociceptin receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Nociceptin receptor agonists Understanding

Nociceptin receptor agonists: Overview

Nociceptin (also known as orphanin FQ) is a 17-amino-acid polypeptide that is structurally related to the opioid peptide dynorphin A. It is the endogenous ligand for the nociceptin opioid (NOP) receptor (formerly referred to as opioid receptor-like-1). Nociceptin does not bind to μ, δ, or κ opioid receptors, and no known exogenous or endogenous opioids bind to the NOP receptor. The neuroanatomical distribution of nociceptin and its receptor are distinct from other opioid peptides. NOP is primarily an inhibitory neuropeptide that acts on neurons to depress synaptic transmission. NOP is reported to modulate pain, stress and anxiety, feeding, learning and memory, reward and addiction, and the functioning of the heart and vessels, airways, kidney, urinary bladder, intestine, and immune cells. The broad spectrum of pharmacological effects of NOP suggests potential therapeutic applications for NOP receptor agonists and/or antagonists.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Nociceptin receptor agonists R&D. The therapies under development are focused on novel approaches for Nociceptin receptor agonists.

Nociceptin receptor agonists Emerging Drugs Chapters

This segment of the Nociceptin receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nociceptin receptor agonists Emerging Drugs

• IMB-115: Imbrium Therapeutics

IMB-115 is an internally discovered compound with a novel mechanism of action in clinical development for the treatment of insomnia associated with alcohol cessation. It is a Nociceptin receptor agonist and is currently in Phase II stage of development to treat Insomnia.

• Buvidal: Camurus

Buvidal is a medicine used to treat dependence on opioid (narcotic) drugs such as heroin or morphine. It is provided as weekly and monthly subcutaneous depot buprenorphine injections available in four weekly strengths (8mg, 16mg, 24mg and 32mg) and three monthly strengths (64mg, 96mg and 128mg) to allow flexible dosing according to patient's individual needs, including initiation of treatment and switching from corresponding doses of daily sublingual buprenorphine. In the EU, Buvidal is indicated for treatment of opioid dependence within a framework of medical, social and psychological treatment, for use in adults and adolescents aged 16 years or over. Currently, it is in Phase III stage of clinical trial evaluation to treat Pain.

Further product details are provided in the report……..

Nociceptin receptor agonists: Therapeutic Assessment

This segment of the report provides insights about the different Nociceptin receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Nociceptin receptor agonists

There are approx. 12+ key companies which are developing the Nociceptin receptor agonists. The companies which have their Nociceptin receptor agonists drug candidates in the most advanced stage, i.e. Phase II include, Imbrium Therapeutics.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Nociceptin receptor agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nociceptin receptor agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nociceptin receptor agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nociceptin receptor agonists drugs.

Nociceptin receptor agonists Report Insights

• Nociceptin receptor agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nociceptin receptor agonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Nociceptin receptor agonists drugs?
• How many Nociceptin receptor agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nociceptin receptor agonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nociceptin receptor agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nociceptin receptor agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Imbrium Therapeutics
• Camurus
• INSYS Therapeutics
• Alkermes
• Aoxing Pharmaceutical Company
• Tris Pharma
• Chiesi Farmaceutici
• Alar Pharmaceuticals
• iX Biopharma
• Grunenthal
• Lyndra Therapeutics
• Zealand Pharma
• Faran Shirin

Key Products

• IMB-115
• Buvidal
• Buprenorphine sublingual
• ALKS 33-BUP
• Naloxone/buprenorphine
• PRK-101
• ALA-1000
• BnoX
• Nociceptin/orphanin FQ peptide receptor agonist therapeutic
• LYN-013
• ZP-120